Quick Answer
NeuroPace Inc reported Cash and Equivalents of $21.69 million for fiscal year 2025.
NeuroPace Inc Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $21.69M | +61.5% |
| 2024 | $13.43M | -25.6% |
| 2023 | $18.06M | +173.4% |
| 2022 | $6.61M | -65.6% |
| 2021 | $19.19M | -27.3% |
| 2020 | $26.39M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.65M | +33.9% | -9.7% |
| June 30, 2025 | $22.86M | +78.0% | -15.4% |
| March 31, 2025 | $27.02M | +107.9% | +101.2% |
| December 31, 2024 | $13.43M | -25.6% | -12.9% |
| September 30, 2024 | $15.42M | +58.7% | +20.0% |
| June 30, 2024 | $12.84M | +63.5% | -1.2% |
| March 31, 2024 | $13.00M | +93.4% | -28.0% |
| December 31, 2023 | $18.06M | +173.4% | +85.8% |
- NeuroPace Inc showed an increase of +61.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, NeuroPace Inc’s cash and equivalents has declined by 17.8% (from $26.39 million to $21.69 million).
- The most recent figure is from NeuroPace Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: